Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Search results for

There are 22,066 results that match your search.22,066 results
  • Developing IP is essential for companies that want to add value to commodity products. David Haigh, CEO of Brand Finance, explains how some of Africa's biggest brands are leading the way
  • When creating trade marks, pharmaceutical companies often choose words that are similar to the generic names of the International Nonproprietary Name (INN) system administered by the World Health Organization (WHO). These marks frequently incorporate the first or last syllables of the relevant INN. The chart below provides samples of trademarks registered in Class 5 for pharmaceutical products that are similar to an INN.
  • Claiming joint-inventor status after a patent has been granted in Taiwan does not necessarily give the claimant the right to the patent.
  • On July 2 2009 the Republic of Poland acceded to the Geneva Act (1999) of the Hague Agreement, which enables the protection of industrial designs in a number of member states and intergovernmental organisations by filing a single international application with the International Bureau of the World Intellectual Property Organization. At present, there are 35 contracting parties to the Geneva Act, while the total number of contracting parties to the Hague Agreement amounts to 56.
  • Last March Korea's National Assembly Committee on Culture, Sports, Tourism, Broadcasting & Communications passed a bill to amend the country's copyright laws to include a so called "three strikes" law to ban illegal uploading of copyright works of others. Despite a great deal of anxiety by many over the passage of the bill, especially from the online community, the revised copyright law came into effect on July 23 this year.
  • A generic drug is a drug in which the patent term relating to the active ingredient has expired. Under the Pharmaceutical Affairs Act, the approval of the Ministry of Health, Labour and Welfare (the MHLW) is required for any manufacture and marketing of drugs, and as a matter of course, the same rule would be applicable to generic drugs. Although the application procedure for the approval of generic drugs is easier than that for the approval of new drugs, generic drugs are subject to certain restrictions.
  • On September 3 2009 the European Court of Justice (ECJ) gave its ruling in Case C-482/07 on prejudicial questions regarding the interpretation of Regulations (EEC) No 1768/92, concerning Supplementary Protection Certificates (SPCs) for medicinal products and Regulation (EC) No 1610/96, which concerns SPCs for plant protection products.
  • The High Court of Kuala Lumpur has, in a recent decision of its own, considered whether it has the powers to rectify the Trade Mark Register in an action to expunge a trade mark by unlawful proprietors.
  • The topic of parallel imports, and the difference between international and national/regional exhaustion of rights in various jurisdictions, is a perennial favourite with Managing IP. Readers have enjoyed the adventures of IP owners and importers in Australia (Ralph Lauren, May 2008), Russia (Porsche, March 2009), France/EC (Dior, April 27 2009), DR/CAFTA (Supplement – Brand Management Focus 2009) and China (Supplement – China Focus 2009).
  • Argentine Trademark Law protects both products and service marks. Under the Law, the ownership of a trade mark and the right to the exclusive use thereof are acquired by registration in accordance with Section 4 of Law 22,362 (trade mark law), which has adopted the attributive system. Consequently, if there is no registry of a trade mark, there is no right thereto.